Lipocalin 2 enhances mesenchymal stem cell-based cell therapy in acute kidney injury rat model.

Szczegóły
Abstrakt

Tytuł:: Lipocalin 2 enhances mesenchymal stem cell-based cell therapy in acute kidney injury rat model.
Autorzy:: Roudkenar MH; Department of Medical Biotechnology, Paramedicine Faculty, Guilan University of Medical Sciences, Rasht, Iran. .; Neuroscience Research Center, Guilan University of Medical Sciences, Rasht, Iran. .
Halabian R; Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Tehrani HA; Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Amiri F; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Jahanian-Najafabadi A; Department of Pharmaceutical Biotechnology, and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran.
Roushandeh AM; Anatomical Sciences Department, Medicine Faculty, Hamadan University of Medical Sciences, Hamadan, Iran.
Abbasi-Malati Z; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Kuwahara Y; Department of Radiation Biology and Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 4-4-1, Komatsushima, Aoba-ku, Sendai, 981-8558, Miyagi, Japan.
Źródło:: Cytotechnology [Cytotechnology] 2018 Feb; Vol. 70 (1), pp. 103-117. Date of Electronic Publication: 2017 Jun 02.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: : Hingham, MA : Kluwer Academic Publishers
Original Publication: Dordrecht ; Boston : Martinus Nijhoff Publishers, c1988-
References:: Transpl Immunol. 2004 Apr;12(3-4):219-27. (PMID: 15157916)
Tohoku J Exp Med. 2012;226(1):29-36. (PMID: 22186034)
Am J Physiol Renal Physiol. 2007 May;292(5):F1626-35. (PMID: 17213465)
J Urol. 2010 Jul;184(1):26-33. (PMID: 20478602)
Lancet. 2005 Apr 2-8;365(9466):1231-8. (PMID: 15811456)
Arch Med Res. 2008 Aug;39(6):560-6. (PMID: 18662586)
BMJ. 2013 Aug 28;347:f4930. (PMID: 23985310)
Kidney Int. 2012 May;81(10 ):969-82. (PMID: 22278021)
Kidney Int. 2011 Jul;80(1):29-40. (PMID: 21562469)
Mol Ther. 2002 Dec;6(6):710-7. (PMID: 12498767)
J Am Soc Nephrol. 2007 Nov;18(11):2921-8. (PMID: 17942965)
Int J Nephrol. 2011;2011:762634. (PMID: 21660314)
Stem Cells Dev. 2009 Apr;18(3):475-85. (PMID: 18564903)
J Am Soc Nephrol. 2006 Jul;17 (7):1970-8. (PMID: 16762988)
J Transl Med. 2012 Dec 05;10:243. (PMID: 23217165)
J Am Soc Nephrol. 2004 Dec;15(12 ):3073-82. (PMID: 15579510)
Am J Physiol Renal Physiol. 2011 Jan;300(1):F207-18. (PMID: 20943766)
Postgrad Med. 2013 Nov;125(6):82-93. (PMID: 24200764)
Cell Biol Int. 2015 Feb;39(2):152-63. (PMID: 25049146)
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93. (PMID: 23744003)
Stem Cells Dev. 2011 Jan;20(1):67-75. (PMID: 20446810)
Cell Stress Chaperones. 2013 Nov;18(6):785-800. (PMID: 23620204)
Circ J. 2011;75(11):2683-91. (PMID: 21828931)
Cell Transplant. 2013;22(3):423-36. (PMID: 22889699)
Am J Kidney Dis. 2002 Aug;40(2):221-6. (PMID: 12148093)
Endocrinology. 2012 Nov;153(11):5361-72. (PMID: 23024264)
World J Stem Cells. 2014 Nov 26;6(5):644-50. (PMID: 25426262)
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1834-9. (PMID: 16446425)
Int J Cancer. 2004 Oct 20;112(1):100-12. (PMID: 15305381)
Curr Stem Cell Res Ther. 2009 Jan;4(1):2-8. (PMID: 19149624)
J Am Soc Nephrol. 2004 Jul;15(7):1794-804. (PMID: 15213267)
Stem Cell Res Ther. 2011 Mar 07;2(2):12. (PMID: 21385372)
Toxicology. 2010 Nov 9;277(1-3):49-58. (PMID: 20816719)
J Transl Med. 2011 Jul 06;9:105. (PMID: 21733181)
Semin Nephrol. 2000 Jan;20(1):4-19. (PMID: 10651214)
Crit Care. 2006;10(3):R73. (PMID: 16696865)
Stem Cells. 2006 Feb;24(2):416-25. (PMID: 16253984)
Circulation. 2002 Jan 1;105(1):93-8. (PMID: 11772882)
Adv Chronic Kidney Dis. 2008 Jul;15(3):222-34. (PMID: 18565474)
J Am Soc Nephrol. 2009 Aug;20(8):1754-64. (PMID: 19470675)
Nephrol Dial Transplant. 2009 Nov;24(11):3265-8. (PMID: 19318357)
Toxicol Lett. 2013 Mar 13;217(3):235-42. (PMID: 23287709)
Cell Stress Chaperones. 2015 Mar;20(2):237-51. (PMID: 25527070)
Invest New Drugs. 2000 Aug;18(3):281-9. (PMID: 10958599)
Stem Cell Res Ther. 2010 Oct 26;1(4):32. (PMID: 20977782)
Curr Opin Nephrol Hypertens. 2006 Jul;15(4):442-9. (PMID: 16775460)
Kidney Int. 2006 Sep;70(6):1120-6. (PMID: 16850028)
Gut. 1996 Mar;38(3):414-20. (PMID: 8675096)
J Am Soc Nephrol. 2009 Jan;20(1):223-8. (PMID: 19020007)
Grant Information:: 91004674 Iran National Science Foundation
Contributed Indexing:: Keywords: Acute kidney injury; Cell therapy; Lipocalin 2; Mesenchymal stem cells
Entry Date(s):: Date Created: 20170603 Latest Revision: 20191120
Update Code:: 20240104
PubMed Central ID:: PMC5809639
DOI:: 10.1007/s10616-017-0107-2
PMID:: 28573544
: Czasopismo naukowe

Full Text Finder

Acute kidney injury (AKI) is one of the most common health-threatening diseases in the world. There is still no effective medical treatment for AKI. Recently, Mesenchymal stem cell (MSC)-based therapy has been proposed for treatment of AKI. However, the microenvironment of damaged kidney tissue is not favorable for survival of MSCs which would be used for therapeutic intervention. In this study, we genetically manipulated MSCs to up-regulate lipocalin-2 (Lcn2) and investigated whether the engineered MSCs (MSC-Lcn2) could improve cisplatin-induced AKI in a rat model. Our results revealed that up-regulation of Lcn2 in MSCs efficiently enhanced renal function. MSC Lcn2 up-regulates expression of HGF, IGF, FGF and VEGF growth factors. In addition, they reduced molecular biomarkers of kidney injury such as KIM-1 and Cystatin C, while increased the markers of proximal tubular epithelium such as AQP-1 and CK18 following cisplatin-induced AKI. Overall, here we over-expressed Lcn2, a well-known cytoprotective factor against acute ischemic renal injury, in MSCs. This not only potentiated beneficial roles of MSCs for cell therapy purposes but also suggested a new modality for treatment of AKI.

Informacja